<DOC>
	<DOC>NCT03084965</DOC>
	<brief_summary>Retrospective Study of Patients With Type 2 Diabetes Mellitus on Dapagliflozin Therapy in Taiwan</brief_summary>
	<brief_title>Retrospective Study of Patients With Type 2 Diabetes Mellitus on Dapagliflozin Therapy in Taiwan</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<criteria>1. Outpatient equal to or more than 20 years of age. 2. T2DM patient initiated dapagliflozin after May 1st 2016 as a second line or third line oral antidiabetic therapy, either as addon or switching from one to another. Or initiating dapagliflozin as adjunctive therapy for T2DM subjects treated with insulin. 3. Completed followup of at least 6 months regardless of continuation on dapagliflozin therapy. 4. Will provide completed and signed written informed consents. 1. Subjects with a history of SGLT2 inhibitor therapy other than dapagliflozin prior to Baseline. 2. Subjects with Type 1 diabetes. 3. Treatment with other investigational drugs concurrently during the retrospective data collection period.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>